Pharmaceutical compositions targeting WNT pathway proteins
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.
Enzo Biochem, Inc. Enzo Therapeutics, Inc.
C A A A C A C A A A A C A A A A A A A
C07K A61K A61P A61P C07K A61P C07K A61P A61K A61P A61P C07K A61P A61P A61P A61P A61P A61K A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
James J. Xiaofeng Joshua
Donegan Li Rabbani